Different Cardio-Selective ß-Blockers and the Prevention of Exaggerated Blood Pressure Response During Exercise: A Retrospective Cross-Sectional Study.

Gurbet Özge Mert, Emre Şener, Ahmet Serdar Yılmaz, Furkan Yetmiş, Ezgi Çamlı, Fatih Enes Durmaz, Muhammet Dural, Yüksel Çavuşoğlu, Selda Murat, Bülent Görenek, Kadir Uğur Mert
{"title":"Different Cardio-Selective ß-Blockers and the Prevention of Exaggerated Blood Pressure Response During Exercise: A Retrospective Cross-Sectional Study.","authors":"Gurbet Özge Mert, Emre Şener, Ahmet Serdar Yılmaz, Furkan Yetmiş, Ezgi Çamlı, Fatih Enes Durmaz, Muhammet Dural, Yüksel Çavuşoğlu, Selda Murat, Bülent Görenek, Kadir Uğur Mert","doi":"10.5543/tkda.2023.73480","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>The aim of this study was to analyze the role of various ß-blockers in managing exercise-induced blood pressure escalations, referred to as exaggerated blood pressure response (eBPR). Despite the importance of this phenomenon, there is limited data on the efficacy of ß-blockers in controlling eBPR.</p><p><strong>Method: </strong>Our retrospective cohort for this study comprised 2,803 individuals who underwent treadmill tests from January 2016 to February 2018. A further subgroup analysis of 1,258 patients receiving ß-blocker treatment was performed to evaluate the influence of different ß-blockers on eBPR.</p><p><strong>Results: </strong>The results demonstrated that ß-blockers play a significant role in mitigating the occurrence of eBPR (P = 0.026), irrespective of the specific type of ß-blocker. Additionally, no significant variance was observed in the development of eBPR among the different ß-blocker groups (P = 0.532 for systolic blood pressure (BP); P = 0.068 for diastolic BP). This finding remained consistent even among the 992 hypertensive patients, where no notable association was found between the type of ß-blocker and the development of eBPR (P = 0.736 for systolic BP; P = 0.349 for diastolic BP). It is noteworthy that patients using ß-blockers had unique clinical and demographic attributes.</p><p><strong>Conclusion: </strong>Our study suggests that ß-blockers can potentially deter the development of eBPR during physical activity, a benefit that is consistent across all types of ß-blockers. The study sheds light on prospective randomized studies on the use of eBPR as a new treatment target.</p>","PeriodicalId":94261,"journal":{"name":"Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir","volume":"52 1","pages":"27-35"},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5543/tkda.2023.73480","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: The aim of this study was to analyze the role of various ß-blockers in managing exercise-induced blood pressure escalations, referred to as exaggerated blood pressure response (eBPR). Despite the importance of this phenomenon, there is limited data on the efficacy of ß-blockers in controlling eBPR.

Method: Our retrospective cohort for this study comprised 2,803 individuals who underwent treadmill tests from January 2016 to February 2018. A further subgroup analysis of 1,258 patients receiving ß-blocker treatment was performed to evaluate the influence of different ß-blockers on eBPR.

Results: The results demonstrated that ß-blockers play a significant role in mitigating the occurrence of eBPR (P = 0.026), irrespective of the specific type of ß-blocker. Additionally, no significant variance was observed in the development of eBPR among the different ß-blocker groups (P = 0.532 for systolic blood pressure (BP); P = 0.068 for diastolic BP). This finding remained consistent even among the 992 hypertensive patients, where no notable association was found between the type of ß-blocker and the development of eBPR (P = 0.736 for systolic BP; P = 0.349 for diastolic BP). It is noteworthy that patients using ß-blockers had unique clinical and demographic attributes.

Conclusion: Our study suggests that ß-blockers can potentially deter the development of eBPR during physical activity, a benefit that is consistent across all types of ß-blockers. The study sheds light on prospective randomized studies on the use of eBPR as a new treatment target.

不同心肌选择性 ß-受体阻滞剂与防止运动时血压反应过高:一项回顾性横断面研究。
研究目的本研究旨在分析各种ß-受体阻滞剂在控制运动引起的血压升高(即夸张血压反应(eBPR))中的作用。尽管这一现象十分重要,但有关ß-阻断剂控制eBPR疗效的数据却十分有限:本研究的回顾性队列包括 2016 年 1 月至 2018 年 2 月期间接受跑步机测试的 2803 人。对1258名接受ß-受体阻滞剂治疗的患者进行了进一步的亚组分析,以评估不同ß-受体阻滞剂对eBPR的影响:结果表明,无论ß-受体阻滞剂的具体类型如何,ß-受体阻滞剂在减轻eBPR发生率方面都发挥着重要作用(P = 0.026)。此外,在不同的ß-受体阻滞剂组别中,eBPR的发生率并无明显差异(收缩压P = 0.532;舒张压P = 0.068)。即使在 992 名高血压患者中,也没有发现ß-受体阻滞剂的类型与 eBPR 的发生有明显关联(收缩压的 P = 0.736;舒张压的 P = 0.349)。值得注意的是,使用ß-受体阻滞剂的患者具有独特的临床和人口统计学特征:结论:我们的研究表明,ß-受体阻滞剂有可能阻止体力活动时 eBPR 的发生,所有类型的ß-受体阻滞剂都有这种益处。本研究为将 eBPR 作为新的治疗目标的前瞻性随机研究提供了启示。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信